MedMira Remains Number One in U.S. Hospitals For 2nd Year 2004 CDC Report Demonstrates Excellent Performance of MedMira's Rapid HIV Test HALIFAX, Jan. 18 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that the results of the 2004 U.S. CDC (Centers for Disease Control and Prevention) HIV Rapid Testing performance evaluation showed that MedMira's Reveal(TM) Rapid HIV-1 Antibody Test (Reveal(TM)) remains the test of choice in U.S. hospitals for the second consecutive year. The 2004 CDC study asked participants to evaluate a panel of HIV-positive and negative donor specimens, that were provided by the CDC, using the rapid HIV test utilized at their facility. A total of 384 participating testing sites took part in the study. The study results indicated that the accuracy of the Reveal(TM) test with HIV-positive specimens was 99.6% (compared to the overall study average of 99.4%) and 99.6% for HIV-negative specimens (compared to the overall study average of 99.5%). Additionally, the percentage of participating United States hospitals using MedMira's test increased from 48% to 51% from the 2003 survey (announced August 12, 2004.) The study also showed an increased use of serum/plasma as the sample type of choice for testing by hospitals, with a decrease in oral fluid samples. MedMira's Reveal(TM) is a serum/plasma rapid HIV test. "MedMira prides itself on the high quality and excellent performance of its rapid testing platform," said Hermes Chan, President and COO of MedMira. "The results of this CDC study confirm these performance standards and provide further evidence of the growing demand for Reveal(TM) in the United States." Chan continued, "We are confident that our test will remain the test of choice for the United States hospital sector." A complete copy of the report is available on the CDC website at: http://www.phppo.cdc.gov/mpep/pdf/rapid/HIVRT0408.pdf About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Investor Relations - Dr. James Smith: (902) 450-1588 or e-mail:

Copyright